Interpretation of the Updated British Society of Gastroenterology Guidelines for the diagnosis and treatment of cholangiocarcinoma(2023 Edition)
LIU Yang
RUAN Xiang
DUAN An-qi
LU Kai
ZHANG Yongjie
YU Wen-long
WANG Xiang
Abstract：In 2022,the Liver Section of the British Society of Gastroenterology convened a panel of multidisciplinary experts in the field of cholangiocarcinoma research.Based on recent evidence-based medical data,the panel comprehensively updated the guidelines for the diagnosis and treatment of cholangiocarcinoma.These updates cover a multitude of facets,including epidemiology,pathology,imaging diagnostics,endoscopic examination,surgical treatment,systemic treatment,and radiation therapy.This revision is built upon the Association's 2012 version of the guidelines,outlining 50 recommendations,each accompanied by a detailed explanation.However,given the complexity of cholangiocarcinoma,the diversity of treatment options,and the lack of high-level medical evidence,coupled with the pronounced clinical and molecular heterogeneity among individuals,the recommendations put forth in these guidelines should be viewed as general guiding principles rather than inflexible rules.Application of these guidelines should consider the specific national conditions of China.This guideline serves as a model for formulating high-quality,evidence-based guidelines for biliary surgery.The listing of low-to-medium-level medical evidence and contentious issues within these guidelines also provides direction for future key breakthroughs in cholangiocarcinoma research.These guidelines provide a clear and concise overview while acknowledging the need for flexibility and adaptation in their application.
Keywords：cholangiocarcinomamalignant biliary tract obstructionclinical guidelineevidence-based medicine
Publication Date：2024-03-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：9( 292-299,311 )